ESC Congress Prague 2008

10th Congress of the
European Society of Contraception

“Non-contraceptive impact of contraception
and family planning”

APRIL
30 – MAY 3 2008 PRAGUE, CZECH REPUBLIC


Results
of evaluation of the congress

Legend: 5=excellent 4=good 3=average 2=below average 1=poor

title lecture

content presentation
Congress session 1
– Mood changes/depression 4,14 3,89
– Weight changes 4,00 4,07
– Bone Mineral Density (BMD) 4,35 4,42
– Breakthrough bleeding 3,91 4,00
– How often and why do women discontinue their
contraceptive method? Results from a French population-based survey
4,39 4,53
– Comparison of patients from high risk population with
vs, without thrombotic events while exposed to hormonal contraception
4,11 3,86
Congress session 2 
– WHO Global STI
epidemiology update
4,00 3,96
– Testing for STIs in
family planning setting – How to make it simple?
3,74 3,74
– Guidelines for HPV DNA testing – To test or not to
test?
3,71 3,43
– Genital Chlamydial Infection: has
the risk for tubal factor infertility and adverse pregnancy outcome been
exaggerated?
3,92 3,93
– To screen or not to
screen…are current guidelines for screening all women for Chlamydia
under age 25 being followed in primary care and at family planning
clinics?
3,65 3,53
– First sex: an opportunity of a
lifetime for HIV/AIDS prevention
3,55 3,48
Congress
session 3
– IUD/IUS in nulliparous women 3,63 3,66
– Management of IUD/IUS in special clinical conditions: emergency
contraception, actinomyces, HIV, dysplasia, cancers…
3,77 3,54
– Non-contraceptive benefits 4,24 4,48
– Long-term use/use beyond recommended time 3,91 3,87
– The Swing IUS: innovative design for intrauterine contraception 4,12 4,17
– Contraception in the postnatal period 3,50 3,53
Congress session 4
– The WHO family
planning cornerstones: a living testimony to the power of partnership
4,61 4,23
– Implementation of family planning
guidelines in Europe – adoption and adaptation
4,38 4,61
– Recommended changes in practice 4,50 4,47

Congress session 5
– The challenge of post-abortion contraception 4,23 4,09
– Follow-up after induced abortion: current
practice and evidence
4,47 4,23
– Access to safe
abortion: legal and other obstacles
3,36 3,08
– A
comparison of two dosages of buccal Misoprostol following Mifepristone
for early medical abortion
3,33 3,67
– Expanding
options for in-the-mouth Misoprostol administration following
Mifepristone in medical abortion
3,57 4,00
Forum 2
– Sexual education, sexual health training needs 4,36 4,29
Forum 3
– What is required/minimal criteria/what should be examined
before prescribing
3,88 4,06
Keynote lecture 1
– HPV
vaccination
4,21 4,13
Keynote lecture 2
– Risk of DVT
with new molecules
4,13 4,08
Keynote lecture 3
– New
developments in contraception
4,45 4,41
Plenary
session 1
– Metabolic benefits 3,96 4,02
– Menorrhagia 3,93 3,98
– Cycle-related symptoms 4,25 4,35
Plenary session 2
– Passion, love and relationship 4,48 4,54
– Hormones and sexual behaviour 4,22 4,19
– Sexual problems in the family planning
consultation-what to do
4,21 4,11


 

home

Scroll to Top